Business Context and Reporting Period
This Form 8-K Current Report was filed by IOVANCE BIOTHERAPEUTICS, INC. on March 5, 2021, with the report date finalized on March 11, 2021. The filing addresses corporate governance changes under Item 5.02 regarding the departure of an officer and the appointment of a new Principal Accounting Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: Michael Swartzburg, Vice President, Finance and interim Principal Accounting Officer, resigned effective March 5, 2021. He agreed to continue serving as Vice President, Finance through March 19, 2021.
- Appointment: On March 11, 2021, the Board of Directors appointed Jean-Marc Bellemin, the Company's current Chief Financial Officer (since December 2020), as the new Principal Accounting Officer.
Management Commentary and Risks
The filing provides background on the new appointee, Mr. Bellemin, noting his prior experience as CFO at Gritstone Oncology, Inc. and senior financial roles at Actelion Pharmaceuticals and Guerbet Group. No specific risks, contingencies, unusual items, or forward-looking guidance are disclosed in this document.
Investor Verification Checklist
- Confirm the transition timeline for the Principal Accounting Officer role between Mr. Swartzburg and Mr. Bellemin.
- Verify if the resignation of Mr. Swartzburg impacts the Company's ongoing financial reporting or internal controls.
- Review subsequent filings for any financial data or strategic updates not included in this personnel-focused report.